Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Announces Year End 2025 Operating and Financial Results

GlobeNewswire 1 day ago

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

GlobeNewswire 10 days ago

ProQR Announces Planned Changes to Board Composition

GlobeNewswire February 9, 2026

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

GlobeNewswire January 8, 2026

ProQR to Participate in 8th Annual Evercore Healthcare Conference

GlobeNewswire December 1, 2025

ProQR Announces Third Quarter 2025 Operating and Financial Results

GlobeNewswire November 6, 2025

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

GlobeNewswire October 20, 2025

ProQR to Participate in Upcoming Investor Conferences in October 2025

GlobeNewswire October 13, 2025

ProQR Announces Second Quarter 2025 Operating and Financial Results

GlobeNewswire August 7, 2025

ProQR Announces Upcoming Presentation at RNA Editing Summit

GlobeNewswire July 28, 2025

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

GlobeNewswire June 26, 2025

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

GlobeNewswire May 12, 2025

ProQR Announces First Quarter 2025 Operating and Financial Results

GlobeNewswire May 8, 2025

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

GlobeNewswire May 2, 2025

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

GlobeNewswire May 1, 2025

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

GlobeNewswire April 14, 2025

ProQR Announces Year End 2024 Operating and Financial Results

GlobeNewswire March 13, 2025

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

GlobeNewswire December 11, 2024

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

GlobeNewswire December 10, 2024

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

GlobeNewswire December 5, 2024

Podcasts